Literature DB >> 22915069

Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes.

Kalyani D Panse1, Leanne E Felkin, Marina M López-Olañeta, Jesús Gómez-Salinero, María Villalba, Lucía Muñoz, Kazuto Nakamura, Masayuki Shimano, Kenneth Walsh, Paul J R Barton, Nadia Rosenthal, Enrique Lara-Pezzi.   

Abstract

Follistatins are extracellular inhibitors of the TGF-β family ligands including activin A, myostatin and bone morphogenetic proteins. Follistatin-like 3 (FSTL3) is a potent inhibitor of activin signalling and antagonises the cardioprotective role of activin A in the heart. FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown. Here, we show that the production of FSTL3 by cardiomyocytes contributes to the paracrine activation of cardiac fibroblasts, inducing changes in cell adhesion, promoting proliferation and increasing collagen production. We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis. However, full activation requires additional factors, and we identify connective tissue growth factor as a FSTL3 binding partner in this process. Together, our data unveil a novel mechanism of paracrine communication between cardiomyocytes and fibroblasts that may provide potential as a therapeutic target in heart remodelling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915069     DOI: 10.1007/s12265-012-9400-9

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  55 in total

1.  Reverse remodelling and recovery from heart failure are associated with complex patterns of gene expression.

Authors:  Leanne Elizabeth Felkin; Enrique A Lara-Pezzi; Jennifer L Hall; Emma J Birks; Paul J R Barton
Journal:  J Cardiovasc Transl Res       Date:  2011-03-22       Impact factor: 4.132

2.  Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy.

Authors:  T Yamazaki; I Komuro; S Kudoh; Y Zou; I Shiojima; Y Hiroi; T Mizuno; K Maemura; H Kurihara; R Aikawa; H Takano; Y Yazaki
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

3.  Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts.

Authors:  T Yokoyama; K Sekiguchi; T Tanaka; K Tomaru; M Arai; T Suzuki; R Nagai
Journal:  Am J Physiol       Date:  1999-06

4.  FLRG, an activin-binding protein, is a new target of TGFbeta transcription activation through Smad proteins.

Authors:  L Bartholin; V Maguer-Satta; S Hayette; S Martel; M Gadoux; S Bertrand; L Corbo; C Lamadon; A M Morera; J P Magaud; R Rimokh
Journal:  Oncogene       Date:  2001-09-06       Impact factor: 9.867

5.  A gene expression profile of the myocardial response to clenbuterol.

Authors:  Enrique Lara-Pezzi; Cesare M N Terracciano; Gopal K R Soppa; Ryszard T Smolenski; Leanne E Felkin; Magdi H Yacoub; Paul J R Barton
Journal:  J Cardiovasc Transl Res       Date:  2009-03-13       Impact factor: 4.132

6.  Protein kinase C epsilon mediates angiotensin II-induced activation of beta1-integrins in cardiac fibroblasts.

Authors:  Philipp Stawowy; Christian Margeta; Florian Blaschke; Carsten Lindschau; Chantel Spencer-Hänsch; Michael Leitges; Giuseppe Biagini; Eckart Fleck; Kristof Graf
Journal:  Cardiovasc Res       Date:  2005-04-07       Impact factor: 10.787

Review 7.  Molecular changes occurring during reverse remodelling following left ventricular assist device support.

Authors:  Emma J Birks; Robert S George
Journal:  J Cardiovasc Transl Res       Date:  2010-09-04       Impact factor: 4.132

8.  Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.

Authors:  Fumitaka Kuwahara; Hisashi Kai; Keisuke Tokuda; Mamiko Kai; Akira Takeshita; Kensuke Egashira; Tsutomu Imaizumi
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

9.  Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury.

Authors:  Yuichi Oshima; Noriyuki Ouchi; Masayuki Shimano; David R Pimentel; Kyriakos N Papanicolaou; Kalyani D Panse; Kunihiro Tsuchida; Enrique Lara-Pezzi; Se-Jin Lee; Kenneth Walsh
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

10.  A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration.

Authors:  Enrique Lara-Pezzi; Nadine Winn; Angelika Paul; Karl McCullagh; Esfir Slominsky; Maria Paola Santini; Foteini Mourkioti; Padmini Sarathchandra; Satsuki Fukushima; Ken Suzuki; Nadia Rosenthal
Journal:  J Cell Biol       Date:  2007-12-17       Impact factor: 10.539

View more
  16 in total

Review 1.  Advances in induced pluripotent stem cells, genomics, biomarkers, and antiplatelet therapy highlights of the year in JCTR 2013.

Authors:  Emanuele Barbato; Enrique Lara-Pezzi; Craig Stolen; Angela Taylor; Paul J Barton; Jozef Bartunek; Paul Iaizzo; Daniel P Judge; Lorrie Kirshenbaum; Burns C Blaxall; Andre Terzic; Jennifer L Hall
Journal:  J Cardiovasc Transl Res       Date:  2014-07       Impact factor: 4.132

2.  Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors.

Authors:  Pei-Suen Tsou; Jonathan D Wren; M Asif Amin; Elena Schiopu; David A Fox; Dinesh Khanna; Amr H Sawalha
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

3.  Follistatin-like 3 suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose.

Authors:  Xiaohong Wang; Liyin Shi; Zhe Han; Baoshan Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Guidelines for translational research in heart failure.

Authors:  Enrique Lara-Pezzi; Philippe Menasché; Jean-Hugues Trouvin; Lina Badimón; John P A Ioannidis; Joseph C Wu; Joseph A Hill; Walter J Koch; Albert F De Felice; Peter de Waele; Valérie Steenwinckel; Roger J Hajjar; Andreas M Zeiher
Journal:  J Cardiovasc Transl Res       Date:  2015-01-21       Impact factor: 4.132

Review 5.  Follistatin-like 1 and its paralogs in heart development and cardiovascular disease.

Authors:  Martin Horak; DeLisa Fairweather; Piia Kokkonen; David Bednar; Julie Bienertova-Vasku
Journal:  Heart Fail Rev       Date:  2022-07-22       Impact factor: 4.654

Review 6.  Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.

Authors:  Ryan G Walker; Tommaso Poggioli; Lida Katsimpardi; Sean M Buchanan; Juhyun Oh; Sam Wattrus; Bettina Heidecker; Yick W Fong; Lee L Rubin; Peter Ganz; Thomas B Thompson; Amy J Wagers; Richard T Lee
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

7.  Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate.

Authors:  Aaron Kunamalla; Jason Ng; Vamsi Parini; Shin Yoo; Kate A McGee; Todd T Tomson; David Gordon; Edward B Thorp; Jon Lomasney; Qiang Zhang; Sanjiv Shah; Suzanne Browne; Bradley P Knight; Rod Passman; Jeffrey J Goldberger; Gary Aistrup; Rishi Arora
Journal:  Circ Res       Date:  2016-05-23       Impact factor: 17.367

Review 8.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

9.  Intravenous delivery of adeno-associated virus 9-encoded IGF-1Ea propeptide improves post-infarct cardiac remodelling.

Authors:  Enrique Gallego-Colon; Maria Villalba; Joanne Tonkin; Francisco Cruz; Juan Antonio Bernal; Luis J Jimenez-Borregureo; Michael D Schneider; Enrique Lara-Pezzi; Nadia Rosenthal
Journal:  NPJ Regen Med       Date:  2016-06-09

10.  Effects of the Activin A-Follistatin System on Myocardial Cell Apoptosis through the Endoplasmic Reticulum Stress Pathway in Heart Failure.

Authors:  Miao Liu; Cuiying Mao; Jiayu Li; Fanglei Han; Ping Yang
Journal:  Int J Mol Sci       Date:  2017-02-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.